Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now?

References

• Hahn BH. Systemic lupus erythematosus. In: Jameson J, editors. Harrison’s principles of internal medicine, 20th edition. Columbus: McGraw Hill. 2018. p. 2515–2526.
   Google Scholar
• Tanaka Y, Kubo S, Iwata S, et al. B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus. Clin Immunol. 2017;186:21–25. doi: 10.1016/j.clim.2017.07.010
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Gladman DD, Ibañez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012;64(1):132–137. doi: 10.1002/acr.20648
   PubMed Web of Science ®Google Scholar
• Aringer M, Costenbader K, Daikh D, et al. European league against Rheumatism/American College of rheumatology classification criteria for systemic lupus erythematosus. Arthritis & Rheumat. 2019;71:1400–1412. doi: 10.1002/art.40930
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Mosca M, Schneider M, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958–967. doi: 10.1136/annrheumdis-2013-205139
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Bertsias G, Doria A, et al. DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8:e000538. doi: 10.1136/lupus-2021-000538
   PubMed Web of Science ®Google Scholar
• Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615–1621. doi: 10.1136/annrheumdis-2015-207726
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18. doi: 10.1136/ard-2022-223356
   PubMed Web of Science ®Google Scholar
• Vukelic M, Li Y, Kyttaris VC. Novel treatments in lupus front immunol. Front Immunol. 2018;9:2658. doi: 10.3389/fimmu.2018.02658
   PubMed Web of Science ®Google Scholar
• Tanaka Y. State-of-the-art treatment of systemic lupus erythematosus. Int J Of Rheum Dis. 2020;23(4):465–471. doi: 10.1111/1756-185X.13817
   PubMed Web of Science ®Google Scholar
• Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–2121. doi: 10.1056/NEJMra1100359
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–233. doi: 10.1002/art.27233
   PubMed Web of Science ®Google Scholar
• Mysler EF, Spindler AJ, Brunetta P, et al. Efficacy and safety of Ocrelizumab in active proliferative lupus nephritis results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65(9):2368–2379. doi: 10.1002/art.38037
   PubMed Web of Science ®Google Scholar
• Clowse ME, Wallance DJ, Gordon C, et al. Efficacy and safety of Epratuzumab in moderately to severely active systemic lupus erythematosus results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis & Rheumat. 2017;69(2):362–375. doi: 10.1002/art.39856
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Kalunian KC, Dörner T, et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann Rheum Dis. 2022 Jul 7;81(11):1556–1563. doi: 10.1136/ard-2022-222858
   PubMed Web of Science ®Google Scholar
• BLISS-52 Study Group, Navarra S, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731.
   PubMed Web of Science ®Google Scholar
• Zhang F, Bae S, Tanaka Y, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77:355–363. doi: 10.1136/annrheumdis-2017-211631
   PubMed Web of Science ®Google Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211–221. doi: 10.1056/NEJMoa1912196
   PubMed Web of Science ®Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117–1128. doi: 10.1056/NEJMoa2001180
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64:1215–1226. doi: 10.1002/art.34359
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nakayamada S, Yamaoka K, et al. Rituximab in the real-world treatment of lupus nephritis: a retrospective cohort study in Japan. Mod Rheumatol. 2023;33(1):145–153. doi: 10.1093/mr/roac007
   PubMed Web of Science ®Google Scholar
• Niewold TB. Niewold TB: connective tissue diseases: targeting type I interferon in systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(7):377–378. doi: 10.1038/nrrheum.2016.83
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Luo Y, O’Shea JJ, et al. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022 Mar;18(3):133–145. doi: 10.1038/s41584-021-00726-8
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol. 2013;9(3):173. doi: 10.1038/nrrheum.2013.7
   PubMed Web of Science ®Google Scholar
• Nakayamada S, Kubo S, Tanaka Y, et al. Chemical JAK inhibitors for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2016;17(16):2215–2225. doi: 10.1080/14656566.2016.1241237
   PubMed Web of Science ®Google Scholar
• Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–1421. doi: 10.1126/science.8197455
   PubMed Web of Science ®Google Scholar
• Liongue C, Ward AC. Evolution of the JAK-STAT pathway. JAKSTAT. 2013;2(1):e22756. doi: 10.4161/jkst.22756
   PubMedGoogle Scholar
• Kubo S, Nakayamada S, Sakata K, et al. Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system. Front Immunol. 2018;9:1510. doi: 10.3389/fimmu.2018.01510
   PubMed Web of Science ®Google Scholar
• Kubo S, Yamaoka K, Tanaka Y, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73(12):2192–2198. doi: 10.1136/annrheumdis-2013-203756
   PubMed Web of Science ®Google Scholar
• Maeshima K, Yamaoka K, Tanaka Y, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 2012;64(6):1790–1798. doi: 10.1002/art.34329
   PubMed Web of Science ®Google Scholar
• Kubo S, Nakayamada S, Tanaka Y, et al. Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients. Arthritis & Rheumat. 2017;69(10):2029–2037. doi: 10.1002/art.40180
   PubMed Web of Science ®Google Scholar
• Ma X, Nakayamada S, Tanaka Y, et al. Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. Ann Rheum Dis. 2018;77(9):1354–1361. doi: 10.1136/annrheumdis-2017-212652
   PubMed Web of Science ®Google Scholar
• Teruel M, Alarcón-Riquelme ME. The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned. J Autoimmun. 2016;74:161–175. doi: 10.1016/j.jaut.2016.08.001
   PubMed Web of Science ®Google Scholar
• Goropevšek A, Holcar M, Avčin T. The role of STAT signaling pathways in the pathogenesis of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2017;52(2):164–181. doi: 10.1007/s12016-016-8550-y
   PubMed Web of Science ®Google Scholar
• Hagberg N, Rönnblom L. Interferon-α enhances the IL-12-induced STAT4 activation selectively in carriers of the STAT4 SLE risk allele rs7574865[T]. Ann Rheum Dis. 2019;78(3):429–431. doi: 10.1136/annrheumdis-2018-213836
   PubMed Web of Science ®Google Scholar
• Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. doi: 10.1038/s41467-021-23361-z
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2019;392:222–231. doi: 10.1016/S0140-6736(18)31363-1
   Google Scholar
• Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023 Mar 25;401(10381):1001–1010. doi: 10.1016/S0140-6736(22)02607-1
   PubMedGoogle Scholar
• Petri M, Bruce IN, Dörner T, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet. 2023 Mar 25;401(10381):1011–1019. doi: 10.1016/S0140-6736(22)02546-6
   PubMedGoogle Scholar
• Merrill JT, Tanaka Y, D’cruz D, et al. OP0139 efficacy and safety of ABBV-599 high dose (Elsubrutinib 60 MG and Upadacitinib 30 MG) and Upadacitinib monotherapy for the treatment of systemic Lupus Erythematosus: a phase 2, double-blind, placebo-controlled trial. Ann Rheumatic Dis OP0139 (EULAR2023). 2023;82:91–92. doi: 10.1136/annrheumdis-2023-eular.2402
   Google Scholar
• Werth VP, Fleischmann R, Robern M, et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022 May 30;61(6):2413–2423. doi: 10.1093/rheumatology/keab685
   PubMed Web of Science ®Google Scholar
• Baker M, Chaichian Y, Genovese M, et al. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. RMD Open. 2020;6(3):e001490. doi: 10.1136/rmdopen-2020-001490
   PubMed Web of Science ®Google Scholar
• Watford WT, Hissong BD, O’Shea JJ, et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004;202:139–156. doi: 10.1111/j.0105-2896.2004.00211.x
   PubMed Web of Science ®Google Scholar
• van Vollenhoven R, Hahn BH, Rose S, et al. Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomized placebo-controlled study. Lancet. 2018;392(10155):1330–1339. doi: 10.1016/S0140-6736(18)32167-6
   PubMed Web of Science ®Google Scholar
• Tucci M, Lombardi L, Silvestris F, et al. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol. 2008;154(2):247–254. doi: 10.1111/j.1365-2249.2008.03758.x
   PubMed Web of Science ®Google Scholar
• Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019 Jul 24;11(502):eaaw1736. doi: 10.1126/scitranslmed.aaw1736
   PubMed Web of Science ®Google Scholar
• Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023 Feb;75(2):242–252. doi: 10.1002/art.42391
   PubMed Web of Science ®Google Scholar
• Kahl L, Patel J, van Vollenhoven RF, et al. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. Lupus. 2016;25(13):1420–1430. doi: 10.1177/0961203316640910
   PubMed Web of Science ®Google Scholar
• Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology. 2019;58(10):1755–1766. doi: 10.1093/rheumatology/kez087
   PubMed Web of Science ®Google Scholar
• Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234–243. doi: 10.1038/nrrheum.2017.23
   PubMed Web of Science ®Google Scholar
• Setyawan J, Mu F, Yarur A, et al. Risk of thromboembolic events and associated risk factors, including treatments, in patients with immune-mediated diseases. Clin Ther. 2021;43:1392–1407. doi: 10.1016/j.clinthera.2021.06.008
   PubMed Web of Science ®Google Scholar
• Setyawan J, Azimi N, Strand V, et al. Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019. Drug Saf. 2021;44:889–897. doi: 10.1007/s40264-021-01082-y
   PubMed Web of Science ®Google Scholar